In recent discussions surrounding the strategic stockpile of medicines and medical supplies, Dr. Fatima Al Kaabi, the Director General of the Emirates Drug Authority, emphasized the critical role that local pharmaceutical manufacturers play in ensuring a stable drug supply for the United Arab Emirates. She confidently asserted that the strategic stockpile of medicines and medical supplies is safe and sufficient to meet local market needs, highlighting the efforts made to fortify the nation’s economy and healthcare system.
Local Manufacturing: A Pillar of Drug Security
During a recent tour of various pharmaceutical factories, Dr. Al Kaabi noted that the pharmaceutical sector in the UAE is characterized by stability and preparedness. She mentioned, “The advanced system in place ensures the sustainability of drug availability for the community according to the highest standards of quality and safety.” This sentiment reflects the growing confidence in local manufacturing capabilities, demonstrating how they contribute significantly to the country’s drug security.
Addressing Regional and Global Challenges
Dr. Al Kaabi reassured stakeholders that the Emirates have the capability to respond effectively to changing regional and global circumstances. The local pharmaceutical landscape has seen significant enhancements in both manufacturing capacities and in the development of favorable legislation that promotes sector growth. She underscored the importance of these advancements, asserting that they are essential for maintaining a robust supply chain of medicines.
Quality Control in Production Processes
During her tour, Dr. Al Kaabi received detailed overviews from factory representatives regarding current production capacities, expansion plans, and the advanced technologies applied in manufacturing processes. These insights highlighted the growing role of local pharmaceutical production in stabilizing the national drug market while ensuring the integrity of supply chains. The Emirates Drug Authority continues to work on integrating a comprehensive regulatory environment to support research and development in the pharmaceutical field.
Commitment from Industry Leaders
During her visit to Medisal Pharma and Adkan Pharma, Dr. Al Kaabi observed the production operations firsthand and explored quality assurance measures implemented throughout various stages of production. Neha Srivastava, General Manager of Medisal Pharma, expressed pride in the company’s base in Abu Dhabi and its contribution to strengthening the local pharmaceutical manufacturing system. She praised the Emirates Drug Authority for its role in supporting the readiness of national drug factories, affirming, “We are committed to ensuring the continuous availability of our products in the market to uphold the drug security system in the country.”
Echoing this commitment, Foukeon Sinis, CEO of Adkan Pharma, highlighted the central role of local pharmaceutical manufacturing in ensuring a steady supply of medications. He noted the increasing pressures on global supply chains and reiterated Adkan Pharma’s dedication to meeting local market demands with high-quality drugs. This collaboration with the Emirates Drug Authority is vital for enhancing production capabilities while ensuring compliance with the highest quality and safety standards.